K76.0

Distinguish between simple fatty liver (steatosis) and non-alcoholic steatohepatitis (NASH). While K76.0 is for fatty liver 'not elsewhere classified', a more specific diagnosis like NASH (K75.81) or alcoholic fatty liver (K70.0) should be used if clinically supported.

Example: Patient is a 58 y.o. male with BMI 32 and T2DM, presenting for follow-up of incidentally found fatty liver on a recent abdominal ultrasound. LFTs are mildly elevated (ALT 75, AST 60). No history of significant alcohol use. Physical exam reveals mild hepatomegaly. Given the elevated LFTs in the context of metabolic syndrome, NASH is suspected. Plan: Order FibroScan to assess for fibrosis, further workup for secondary causes, and continue strict glycemic and weight management. Documentation of 'Fatty liver, suspected non-alcoholic steatohepatitis (NASH)' is crucial for defining severity and ongoing management. Patient advised on Mediterranean diet and increased physical activity. Current medications include Metformin and Atorvastatin.

Billing Focus: Specificity of liver condition (steatosis vs. steatohepatitis), clear documentation of 'suspected' or 'presumed' diagnoses if further workup is pending. Link to underlying comorbidities for medical necessity.

Clearly document the presence and management of associated metabolic comorbidities, such as obesity, type 2 diabetes mellitus, and hyperlipidemia. These conditions are highly prevalent with fatty liver and impact patient risk and treatment plans.

Example: 65 y.o. female, known Type 2 Diabetes Mellitus (E11.9, controlled on Metformin), morbid obesity (E66.01, BMI 42), and mixed hyperlipidemia (E78.2, on Atorvastatin). Abdominal MRI confirms diffuse hepatic steatosis (K76.0). Patient reports mild fatigue. Discussion included importance of maintaining strict blood glucose control, weight reduction through dietary changes (referral to dietitian placed), and adherence to lipid-lowering therapy. Continued monitoring of LFTs and HbA1c. Given the constellation of metabolic conditions, the fatty liver is considered part of the metabolic syndrome and is being actively managed in conjunction with her other chronic conditions. This comprehensive approach reflects the complexity of the patient's care.

Billing Focus: Detailed documentation of all co-existing chronic conditions (e.g., T2DM, obesity, hyperlipidemia), as they support the medical necessity for evaluation and management services, imaging, and lab tests. Specificity of each condition (e.g., 'morbid obesity' rather than just 'obesity').

Always specify the etiology of fatty liver when known or strongly suspected. If alcohol-related, use K70.0. If due to other specific causes (e.g., drug-induced), use the appropriate code. K76.0 should be reserved for 'not elsewhere classified' cases after specific etiologies are ruled out or are not applicable.

Example: 50 y.o. male presents with newly elevated LFTs (ALT 90, AST 70) found on routine labs. Abdominal ultrasound shows diffuse fatty liver. Patient denies any alcohol consumption, history of hepatitis, or use of hepatotoxic medications. Workup for viral hepatitis, autoimmune liver disease, and genetic hemochromatosis was negative. Given the absence of other identified causes and the negative workup, the diagnosis is documented as 'Fatty (change of) liver, not elsewhere classified (K76.0), presumed non-alcoholic etiology'. Patient is instructed on lifestyle modifications (diet, exercise) and weight loss. Follow-up LFTs and a FibroScan are planned in 3 months. This detailed documentation supports K76.0 as the most appropriate code after exclusion of other common causes.

Billing Focus: The comprehensive workup and exclusion of other diagnoses justify the use of K76.0. This avoids potential audits where K76.0 might be challenged for lack of specificity if a more precise code could have been used. Billing for the diagnostic workup (labs, imaging) is also supported by the elevated LFTs and need for etiology determination.